Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.

N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.

2.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

3.

Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1.

Ghosh S, Gu F, Wang CM, Lin CL, Liu J, Wang H, Ravdin P, Hu Y, Huang TH, Li R.

Breast Cancer Res Treat. 2014 Oct;147(3):653-9. doi: 10.1007/s10549-014-3132-2. Epub 2014 Sep 19.

4.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America.

Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6. Epub 2009 Dec 10.

5.

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC.

J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-3. Review.

PMID:
19755043
6.

Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.

Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, van Ravesteyn NT, Venier J, Zelen M, Feuer EJ; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2009 Nov 17;151(10):738-47. doi: 10.7326/0003-4819-151-10-200911170-00010. Erratum in: Ann Intern Med. 2010 Jan 19;152(2):136.

7.

Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004.

Shen Y, Dong W, Feig BW, Ravdin P, Theriault RL, Giordano SH.

Cancer. 2009 May 15;115(10):2041-51. doi: 10.1002/cncr.24271.

8.

Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.

Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Green AR, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ.

Clin Cancer Res. 2008 Oct 15;14(20):6625-33. doi: 10.1158/1078-0432.CCR-08-0701.

9.

Building a predictive breast cancer risk model.

Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D.

AMIA Annu Symp Proc. 2007 Oct 11:995.

PMID:
18694095
10.

Overview of randomized trials of systemic adjuvant therapy.

Ravdin P.

Cancer Treat Res. 2008;141:55-62. Review. No abstract available.

PMID:
18274082
11.

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology.

J Clin Oncol. 2007 Nov 20;25(33):5287-312. Epub 2007 Oct 22. Review.

PMID:
17954709
12.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.

Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium.

Nat Clin Pract Oncol. 2006 Oct;3(10):540-51. Review.

PMID:
17019432
13.

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.

Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P.

Curr Med Res Opin. 2006 Aug;22(8):1575-85. Review.

PMID:
16870082
14.

NCCN Task Force Report: Bone Health and Cancer Care.

Theriault RL, Biermann JS, Brown E, Brufsky A, Demers L, Grewal RK, Guise T, Jackson R, McEnery K, Podoloff D, Ravdin P, Shapiro CL, Smith M, Van Poznak CH.

J Natl Compr Canc Netw. 2006 May;4 Suppl 2:S1-20; quiz S21-2.

PMID:
16737674
15.

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.

Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Mar;4 Suppl 1:S1-26. Review.

PMID:
16507275
16.

Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.

Ravdin P.

Lancet. 2002 Jun 22;359(9324):2126-7. No abstract available.

PMID:
12090973
17.

Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.

Gianni L, Dombernowsky P, Sledge G, Martin M, Amadori D, Arbuck SG, Ravdin P, Brown M, Messina M, Tuck D, Weil C, Winograd B.

Ann Oncol. 2001 Aug;12(8):1067-73.

PMID:
11583187
18.

Doctor-patient communication patterns in breast cancer adjuvant therapy discussions.

Siminoff LA, Ravdin P, Colabianchi N, Sturm CM.

Health Expect. 2000 Mar;3(1):26-36.

19.

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel.

J Clin Oncol. 2001 Mar 15;19(6):1865-78. Erratum in: J Clin Oncol 2001 Nov 1;19(21):4185-8. J Clin Oncol 2002 Apr 15;20(8):2213.

PMID:
11251019

Supplemental Content

Loading ...
Support Center